Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-22P is a pseudogene of the U4 small nuclear RNA family, annotated as "RNA, U4 small nuclear 22, pseudogene." Pseudogenes generally do not encode functional products and are not associated with biological function, therapeutic targeting, or disease relevance[1]. There is no evidence of gene expression, protein product, or involvement in normal or pathological processes. For disease or functional studies, the relevant gene is RNU4-2 (U4 small nuclear RNA), which plays a key role in pre-mRNA splicing and is linked to neurodevelopmental disorders when mutated[2][3][5][7]. RNU4-22P itself is not considered a therapeutic target or a functional molecular component. If you seek information about RNU4-2 (the functional gene), please specify accordingly, as that molecule has documented biological and disease roles, including recent links to neurodevelopmental disease[2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 22, pseudogene (RNU4-22P).